Five-year review of HIV-hepatitis B virus (HBV) co-infected patients in a New York City AIDS center.
A retrospective review of 4,721 human immunodeficiency virus (HIV)-infected patients, followed at St. Luke's Roosevelt Hospital Center, New York City, was conducted from January 1, 2005 to December 31, 2009. HIV-Hepatitis B virus (HBV) co-infection rate was 218/4,721, 4.6%. Among co-infected patients, 19 patients (19/218, 8.7%) died; 13 patients (13/19, 68.4%) died from non-acquired immune deficiency syndrome (AIDS) defining including 2 patients with liver failure. More non-survivors (5 patients, 5/19, 26.3%) had liver cirrhosis than those who survived (8 patients, 8/199, 4.0%; P = 0.002). There were more patients with positive HBV e antigen (HBeAg) among non-survivors, (12 patients, 12/19, 63.2%) than among survivors (74 patients, 74/199, 37.2%; P = 0.047). HIV-HBV co-infection is associated with increased overall mortality. Therefore, use of dual active antiretrovirals, particularly, tenofovir (TDF) based regimen for optimal suppression of HIV-HBV and immune restoration with prevention of high risk behaviors may contribute to improved outcomes.
Division of Infectious Diseases, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA.
Jong Hun
JH
Kim
George
G
Psevdos
Victoria
V
Sharp
D000225:Adenine / Q000031:analogs & derivatives / Q000627:therapeutic use; D000328:Adult; D019380:Anti-HIV Agents / Q000627:therapeutic use; D060085:Coinfection / Q000188:drug therapy / Q000401:mortality; D005260:Female; D015658:HIV Infections / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D006509:Hepatitis B / Q000150:complications / Q000175:diagnosis* / Q000188:drug therapy; D006513:Hepatitis B e Antigens / Q000097:blood; D006801:Humans; D008103:Liver Cirrhosis / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009519:New York City; D063065:Organophosphonates / Q000627:therapeutic use; D012189:Retrospective Studies; D000068698:Tenofovir
D019380:Anti-HIV Agents; D006513:Hepatitis B e Antigens; D063065:Organophosphonates; D000068698:Tenofovir; D000225:Adenine